A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

In phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D1. In phase Ib study, the safety and tolerability of BL-M07D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M07D1 in

Trial Details

NCT ID
NCT05461768
Phase
PHASE1
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • BL-M07D1
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Dongguan, Guangdong, China|23.01797,113.74866
  • Guangdong, Guangzhou, China|42.76832,129.33635
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • 1\. Sign the informed consent voluntarily and follow the program requirements
  • 2\. No gender limitation;
  • 3\. Age: ≥18 years old and ≤75 years old (Stage Ia);≥18 years old (Ib);
  • 4\. Expected survival time ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →